Please login to the form below

Not currently logged in
Email:
Password:

Hanover Health opens market access practice

New practice will be led by director Jing Wang-Silvanto

HanoverHanover Health, part of the wider Hanover communications and public affairs consultancy group, has created a new market access-focused practice at its London and Brussels hubs.

Adding to the health specialist's three existing practices - Health Communications and UK and European Health Policy and Advocacy - Healthcare Market Access will be led by director Jing Wang-Silvanto.

Wang-Silvanto joins the new practice from WG Access, where she was director for value access strategy and head of health economics, and also brings client-side expertise from Bristol-Myers Squibb, GlaxoSmithKline and Novartis.

Her team will offer pricing and managed access, early access and payer engagement, and health technology assessment support for pharma clients across Europe.

Andrew Harrison, Hanover's managing director of health, said: “Health system finances are squeezed and there is increased need for companies to demonstrate the value of their products and services.

“There are plenty of market access consultancies, but Hanover's ability to join market access with award-winning policy, advocacy and communications campaigns provides a unique offer that can bring change for clients.

“Market Access is a natural extension of Hanover's health work. For a while clients have asked the team to support pricing, health economics and early access work.

“Our growth in health in the UK and internationally, and in communications as well as policy, gives us the confidence to invest in expanding our services.”

Article by
Rebecca Clifford

21st December 2016

From: Marketing

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Bedrock Group

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
The other side of … blood cancer
To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....
COVID clinical trial
COVID-19 – a catalyst for technology adoption in clinical trials
As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good...

Infographics